Attached files

file filename
EX-32.2 - EX-32.2 - SUPERCONDUCTOR TECHNOLOGIES INCd382449dex322.htm
EX-32.1 - EX-32.1 - SUPERCONDUCTOR TECHNOLOGIES INCd382449dex321.htm
EX-31.2 - EX-31.2 - SUPERCONDUCTOR TECHNOLOGIES INCd382449dex312.htm
EX-31.1 - EX-31.1 - SUPERCONDUCTOR TECHNOLOGIES INCd382449dex311.htm
Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 10-Q

 

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended April 1, 2017

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     

Commission File Number 0-21074

 

 

SUPERCONDUCTOR TECHNOLOGIES INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   77-0158076

(State or other jurisdiction of

incorporation or organization)

 

(IRS Employer

Identification No.)

9101 Wall Street, Suite 1300, Austin, Texas 78754

(Address of principal executive offices & zip code)

(512) 334-8900

(Registrant’s telephone number including area code)

 

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  ☒    No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer      Accelerated filer  
Non-accelerated filer   ☐  (Do not check if a smaller reporting company)    Smaller reporting company  
Emerging growth company       

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐ or No  ☒

We had 10,724,261 shares of our common stock outstanding as of the close of business on May 6, 2017.

 

 

 


Table of Contents

SUPERCONDUCTOR TECHNOLOGIES INC.

INDEX TO FORM 10-Q

Three Months Ended April 1, 2017

 

SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS

     1  

PART I - FINANCIAL INFORMATION

  

ITEM 1. Financial Statements (unaudited)

  
  

Condensed Consolidated Statements of Operations

     2  
  

Condensed Consolidated Balance Sheets

     3  
  

Condensed Consolidated Statements of Cash Flows

     4  
  

Notes to Unaudited Condensed Consolidated Financial Statements.

     5  

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

     14  

ITEM 3. Quantitative and Qualitative Disclosures About Market Risk

     18  

ITEM 4. Controls and Procedures

     18  

PART II - OTHER INFORMATION

  

ITEM 1. Legal Proceedings

     19  

ITEM 1A. Risk Factors

     19  

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds

     20  

ITEM 3. Defaults Upon Senior Securities

     20  

ITEM 4. Mine Safety Disclosures

     20  

ITEM 5. Other Information

     20  

ITEM 6. Exhibits

     20  

SIGNATURES

     21  

 

i


Table of Contents

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for these forward-looking statements. Our forward-looking statements relate to future events or our future performance and include, but are not limited to, statements concerning our business strategy, future commercial revenues, market growth, capital requirements, new product introductions, expansion plans and the adequacy of our funding. Other statements contained in this Report that are not historical facts are also forward-looking statements. We have tried, wherever possible, to identify forward-looking statements by terminology such as “may,” “will,” “could,” “should,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and other comparable terminology.

We caution investors that any forward-looking statements presented in this Report, or that we may make orally or in writing from time to time, are based on our beliefs and assumptions made by, and information currently available to, us. Such statements are based on assumptions and the actual outcome will be affected by known and unknown risks, trends, uncertainties and factors that are beyond our control or ability to predict. Although we believe that our assumptions are reasonable, they are not guarantees of future performance and some will inevitably prove to be incorrect. As a result, our actual future results can be expected to differ from our expectations, and those differences may be material. Accordingly, investors should use caution in relying on past forward-looking statements, which are based on known results and trends at the time they are made, to anticipate future results or trends.

Some of the risks and uncertainties that may cause our actual results, performance or achievements to differ materially from those expressed or implied by forward-looking statements include the following:

 

    our limited cash and a history of losses;

 

    our need to materially grow our revenues from commercial operations and/or to raise additional capital (which financing may not be available on acceptable terms or at all) over the next 12-months to implement our current business plan and maintain our viability;

 

    the performance and use of our equipment to produce wire in accordance with our timetable;

 

    overcoming technical challenges in attaining milestones to develop and manufacture commercial lengths of our high temperature superconducting (HTS) wire;

 

    the possibility of delays in customer evaluation and acceptance of our HTS wire;

 

    the limited number of potential customers and customer pressures on the selling prices of our products;

 

    the limited number of suppliers for some of our components and our HTS wire;

 

    there being no significant backlog from quarter to quarter;

 

    our market being characterized by rapidly advancing technology;

 

    the impact of competitive products, technologies and pricing;

 

    manufacturing capacity constraints and difficulties;

 

    the impact of any financing activity on the level of our stock price;

 

    the dilutive impact of any issuances of securities to raise capital;

 

    cost and uncertainty from compliance with environmental regulations;

 

    local, regional, and national and international economic conditions and events, and the impact they may have on us and our customers; and

 

    if we fail to maintain the listing of our common stock with a U.S. national securities exchange, the liquidity of our common stock could be adversely affected.

For further discussion of these and other factors see, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016.

This Report and all subsequent written and oral forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. We do not undertake any obligation to release publicly any revisions to our forward-looking statements to reflect events or circumstances after the date of this Report.

 

1


Table of Contents

PART I

FINANCIAL INFORMATION

Item 1. Financial Statements

SUPERCONDUCTOR TECHNOLOGIES INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

     Three Months Ended  
     April 1, 2017     April 2, 2016  

Revenues

   $ 1,000     $ 89,000  
  

 

 

   

 

 

 

Costs and expenses:

    

Cost of revenues

     862,000       864,000  

Research and development

     650,000       716,000  

Selling, general and administrative

     1,120,000       1,163,000  
  

 

 

   

 

 

 

Total costs and expenses

     2,632,000       2,743,000  
  

 

 

   

 

 

 

Loss from operations

     (2,631,000     (2,654,000

Other Income and Expense:

    

Adjustments to fair value of warrant derivatives

     (3,000     21,000  

Other income

     5,000       3,000  
  

 

 

   

 

 

 

Net loss

   $ (2,629,000   $ (2,630,000
  

 

 

   

 

 

 

Basic and diluted net loss per common share

   $ (0.26   $ (1.00
  

 

 

   

 

 

 

Basic and diluted weighted average number of common shares outstanding

     9,967,932       2,626,824  
  

 

 

   

 

 

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

2


Table of Contents

SUPERCONDUCTOR TECHNOLOGIES INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

 

     April 1,
2017
    December 31,
2016
 
     (Unaudited)     (See Note)  

ASSETS

    

Current Assets:

    

Cash and cash equivalents

   $ 8,414,000     $ 10,452,000  

Accounts receivable, net

     —         8,000  

Inventories, net

     53,000       68,000  

Prepaid expenses and other current assets

     19,000       109,000  
  

 

 

   

 

 

 

Total Current Assets

     8,486,000       10,637,000  

Property and equipment, net of accumulated depreciation of $9,912,000 and $9,350,000, respectively

     2,929,000       3,491,000  

Patents, licenses and purchased technology, net of accumulated amortization of $954,000 and $948,000, respectively

     1,024,000       990,000  

Other assets

     69,000       96,000  
  

 

 

   

 

 

 

Total Assets

   $ 12,508,000     $ 15,214,000  
  

 

 

   

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

    

Current Liabilities:

    

Accounts payable

   $ 349,000     $ 336,000  

Accrued expenses

     410,000       608,000  
  

 

 

   

 

 

 

Total Current Liabilities

     759,000       944,000  

Other long term liabilities

     177,000       172,000  
  

 

 

   

 

 

 

Total Liabilities

     936,000       1,116,000  
  

 

 

   

 

 

 

Commitments and Contingencies (Notes 5 and 6)

    

Stockholders’ Equity:

    

Preferred stock, $.001 par value, 2,000,000 shares authorized, 328,925 and 333,767 shares issued and outstanding, respectively

     —         —    

Common stock, $.001 par value, 250,000,000 shares authorized, 10,590,928 and 7,353,714 shares issued and outstanding, respectively

     10,000       7,000  

Capital in excess of par value

     316,277,000       316,177,000  

Accumulated deficit

     (304,715,000     (302,086,000
  

 

 

   

 

 

 

Total Stockholders’ Equity

     11,572,000       14,098,000  
  

 

 

   

 

 

 

Total Liabilities and Stockholders’ Equity

   $ 12,508,000     $ 15,214,000  
  

 

 

   

 

 

 

See accompanying notes to the unaudited condensed consolidated financial statements.

Note – December 31, 2016 balances were derived from audited financial statements.

 

3


Table of Contents

SUPERCONDUCTOR TECHNOLOGIES INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

     Three Months Ended  
     April 1, 2017     April 2, 2016  

CASH FLOWS FROM OPERATING ACTIVITIES:

    

Net loss

   $ (2,629,000   $ (2,630,000

Adjustments to reconcile net loss to net cash used in operating activities:

    

Depreciation and amortization

     568,000       580,000  

Stock-based compensation expense

     103,000       261,000  

Adjustments to fair value of warrant derivatives

     3,000       21,000  

Changes in assets and liabilities:

    

Accounts receivable

     9,000       (32,000

Inventories

     15,000       (43,000

Prepaid expenses and other current assets

     90,000       (61,000

Patents and licenses

     (41,000     (50,000

Other assets

     27,000       126,000  

Accounts payable, accrued expenses and other current liabilities

     (183,000     (67,000
  

 

 

   

 

 

 

Net cash used in operating activities

     (2,038,000     (1,895,000
  

 

 

   

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES:

    

Purchases of property and equipment

     —         —    

Net proceeds from the sale of property and equipment

     —         —    
  

 

 

   

 

 

 

Net cash used in investing activities

     —         —    
  

 

 

   

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES:

    

Net proceeds from the sale of common stock

     —         —    

Net proceeds from the exercise of outstanding warrants

     —         —    
  

 

 

   

 

 

 

Net cash provided by financing activities

     —         —    
  

 

 

   

 

 

 

Net decrease in cash and cash equivalents

     (2,038,000     (1,895,000

Cash and cash equivalents at beginning of period

     10,452,000       7,469,000  
  

 

 

   

 

 

 

Cash and cash equivalents at end of period

   $ 8,414,000     $ 5,574,000  
  

 

 

   

 

 

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

4


Table of Contents

SUPERCONDUCTOR TECHNOLOGIES INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. General

Superconductor Technologies Inc. (together with our subsidiaries, “we” or “us”) was incorporated in Delaware on May 11, 1987. We develop and produce high temperature superconducting (HTS) materials and associated technologies. We have generated more than 100 patents as well as proprietary trade secrets and manufacturing expertise. We are now leveraging our key enabling technologies in HTS materials and cryogenics, to pursue emerging opportunities in the electrical grid and in equipment platforms that utilize electrical circuits.

Our initial superconducting products were completed in 1998, and we began delivery to a number of wireless network providers. In the following 14 years, our cost reducing efforts led to the invention of our proprietary, high-yield and high throughput HTS material deposition manufacturing process.

Since 2010, we have focused our research and development efforts on adapting our successful HTS materials deposition techniques to the production of our HTS Conductus® wire for next generation power applications. Our current commercial product revenues come from the sale of our legacy high performance wireless communications infrastructure products. Production of our Conductus wire is our principal opportunity to grow our future revenue.

Historically, we used research and development contracts as a source of funds for our commercial technology development. Although we are not currently involved as either a contractor or subcontractor on contracts with the U.S. government, in November 2016, we were selected as the prime recipient of a $4.5 million program award provided by the U.S. Department of Energy.

The unaudited condensed consolidated financial information furnished herein has been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and reflects all adjustments, consisting only of normal recurring adjustments, which in the opinion of management, are necessary for a fair statement of the results of operations for the periods presented.

The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the accompanying notes. Actual results could differ from those estimates and such differences may be material to the condensed consolidated financial statements. This quarterly report on Form 10-Q should be read in conjunction with our Form 10-K for 2016. The results of operations for the three months ended April 1, 2017 are not necessarily indicative of the results for all of 2017.

2. Summary of Significant Accounting Policies

Basis of Presentation

We have incurred significant net losses since our inception and have an accumulated deficit of $304.7 million. In 2016, we incurred a net loss of $11.1 million and had negative cash flows from operations of $8.1 million. At April 1, 2017, we had $8.4 million in cash and cash equivalents compared to $10.5 million in cash and cash equivalents as of December 31, 2016. Our current forecast is that our existing cash and cash equivalents resources will be sufficient to fund our planned operations into the first quarter of 2018. Unless we can materially grow our revenues from commercial operations, we will need to raise additional capital during the next 12-months to continue to implement our current business plan and maintain our viability. Additional financing may not be available on acceptable terms or at all. If we issue additional equity securities to raise funds, the ownership percentage of our existing stockholders would be reduced. New investors may demand rights, preferences or privileges senior to those of existing holders of common stock. If we cannot raise any needed funds, we might be forced to make further substantial reductions in our operating expenses, which could adversely affect our ability to implement our current business plan and ultimately our viability as a company. These factors raise substantial doubt about our ability to continue as a going concern within one year after the date the condensed consolidated financial statements were issued.

Our plans regarding improving our future liquidity will require us to successfully use our expertise and our technology to generate revenues in various ways, including commercial operations, joint ventures and licenses. We have invested and will continue to invest in our Austin, Texas manufacturing facility to enable us to produce our Conductus wire products. However, delays in the timing of our ability to, including but not limited to, raise additional capital, unexpected production delays, and our ability to sell our Conductus wire products in large scale could substantially impact our estimates used in the determination of expected future cash flows and/or expected future profitability.

 

5


Table of Contents

The accompanying condensed consolidated financial statements do not include any adjustments that may result from the outcome of the uncertainties set forth above. On July 18, 2016, we effected a 1-for-15 reverse stock split of our common stock, or the Reverse Stock Split. As a result of the Reverse Stock Split, every fifteen shares of our pre-Reverse Stock Split common stock were combined and reclassified into one share of our common stock. The Reverse Stock Split did not change the authorized number of shares or the par value of our common stock. Share and per share data included herein has been retroactively restated for the effect of the Reverse Stock Split as applicable. In addition, we identified certain critical accounting policies which affect certain of our more significant estimates and assumptions used in preparing our condensed consolidated financial statements in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016. We have not made any material changes to these policies.

We have reviewed recently issued Financial Accounting Standards Board pronouncements and do not believe they will have a material impact on our condensed consolidated financial statements.

Principles of Consolidation

The interim condensed consolidated financial statements include the accounts of Superconductor Technologies Inc. and its wholly owned subsidiaries. All significant intercompany transactions have been eliminated from the condensed consolidated financial statements.

Cash and Cash Equivalents

Cash and cash equivalents consist of highly liquid investments with original maturities of three months or less. Cash and cash equivalents are maintained with what we believe to be quality financial institutions and exceed FDIC limits. Historically, we have not experienced any losses due to such concentration of credit risk.

Accounts Receivable

We grant uncollateralized credit to our customers. We perform usual and customary credit evaluations of our customers before granting credit. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is our best estimate of the amount of probable credit losses in our existing accounts receivable. We determine the allowance based on historical write-off experience. Past due balances are reviewed for collectability. Accounts balances are charged off against the allowance when we deem it is probable the receivable will not be recovered. We do not have any off-balance sheet credit exposure related to our customers.

Revenue Recognition

Our revenues have principally been derived from the sale of our wireless communications products, and are recognized once all of the following conditions have been met: a) an authorized purchase order has been received in writing, b) the customer’s credit worthiness has been established, c) shipment of the product has occurred, d) title has transferred, and e) if stipulated by the contract, customer acceptance has occurred and all significant vendor obligations, if any, have been satisfied.

Shipping and Handling Fees and Costs

Shipping and handling fees billed to customers are included in net revenues. Shipping and handling fees associated with freight are generally included in cost of revenues.

Warranties

We offer warranties generally ranging from one to five years, depending on the product and negotiated terms of purchase agreements with our customers. Such warranties require us to repair or replace defective product returned to us during such warranty period at no cost to the customer. An estimate by us for warranty related costs is recorded by us at the time of sale based on our actual historical product return rates and expected repair costs. Such costs have been within our expectations.

Indemnities

In connection with the sales and manufacturing of our commercial products, we indemnify, without limit or term, our customers and contract manufacturers against all claims, suits, demands, damages, liabilities, expenses, judgments, settlements and penalties arising from actual or alleged infringement or misappropriation of any intellectual property relating to our products or other claims arising from our products. We cannot reasonably develop an estimate of the maximum potential amount of payments that might be made under our indemnities because of the uncertainty as to whether a claim might arise and how much it might total. Historically, we have not incurred any expenses related to these indemnities.

 

6


Table of Contents

Research and Development Costs

Research and development costs are charged to expense as incurred and include salary, facility, depreciation and material expenses. Research and development costs are charged to research and development expense.

Inventories

Inventories were stated at the lower of cost or market, with costs primarily determined using standard costs, which approximate actual costs utilizing the first-in, first-out method. We review inventory quantities on hand and on order and record, on a quarterly basis, a provision for excess and obsolete inventory and/or vendor cancellation charges related to purchase commitments. If the results of the review determine that a write-down is necessary, we recognize a loss in the period in which the loss is identified, whether or not the inventory is retained. Our April 1, 2017 net inventory value was $53,000, compared to a December 31, 2016 value of $68,000. Our inventory reserves establish a new cost basis for inventory and are not reversed until we sell or dispose of the related inventory. Such provisions are established based on historical usage, adjusted for known changes in demands for such products, or the estimated forecast of product demand and production requirements. Costs associated with idle capacity are charged to expense immediately.

Property and Equipment

Property and equipment are recorded at cost. Equipment is depreciated using the straight-line method over their estimated useful lives ranging from three to five years. Leasehold improvements and assets financed under capital leases are amortized over the shorter of their useful lives or the lease term. Furniture and fixtures are depreciated over seven years. Expenditures for additions and major improvements are capitalized. Expenditures for minor tooling, repairs and maintenance and minor improvements are charged to expense as incurred. When property or equipment is retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the accounts. Gains or losses from retirements and disposals are recorded in selling, general and administration expenses.

Patents, Licenses and Purchased Technology

Patents and licenses are recorded at cost and are amortized using the straight-line method over the shorter of their estimated useful lives or seventeen years.

Other Assets and Investments

The realizability of long-lived assets is evaluated periodically as events or circumstances indicate a possible inability to recover the carrying amount. Long-lived assets that will no longer be used in the business are written off in the period identified since they will no longer be used in operations and generate any positive cash flows for us. Periodically, long-lived assets that will continue to be used by us will need to be evaluated for recoverability. Such evaluation is based on various analyses, including cash flow and profitability projections, as well as alternative uses, such as government contracts or awards. The analyses necessarily involve significant management judgment. Market acceptance and significant revenues from our new Conductus wire is a key assumption in realization of our investment in long-lived assets. In the event the projected undiscounted cash flows are less than net book value of the assets, the carrying value of the assets will be written down to their estimated fair value. We tested our long-lived assets for recoverability during 2016 and at April 1, 2017 and did not believe there was any impairment.

Loss Contingencies

In the normal course of our business we are subject to claims and litigation, including allegations of patent infringement. Liabilities relating to these claims are recorded when it is determined that a loss is probable and the amount of the loss can be reasonably estimated. The costs of our defense in such matters are expensed as incurred. Insurance proceeds recoverable are recorded when deemed probable.

Income Taxes

We recognize deferred tax liabilities and assets based on the differences between the financial statement carrying amounts and the tax bases of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse. Deferred income tax benefit (expense) results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when it is more likely than not that some or all deferred tax assets will not be realized. The guidance further clarifies the accounting for uncertainty in income taxes and sets a consistent framework to determine the

 

7


Table of Contents

appropriate level of tax reserve to maintain for uncertain tax positions. This interpretation uses a two-step approach wherein a tax benefit is recognized if a position is more-likely-than-not to be sustained. The amount of the benefit is then measured to be the highest tax benefit that is greater than 50% likely to be realized and sets out disclosure requirements to enhance transparency of our tax reserves. The adoption of this guidance has not had a material impact on our condensed consolidated financial statements as we concluded our tax positions are highly certain of being settled at 100% of the benefit claimed. Guidance is also provided on the accounting for the related interest and penalties, financial statement and disclosure. We are currently not under examination by any taxing authority nor have we been notified of an impending examination. The oldest California and federal tax years that remain open to possible evaluation and interpretation of our tax position are 2012 and 2013, respectively.

As of December 31, 2016, we had net operating loss carryforwards for federal and state income tax purposes of $344.3 million and $119.6 million, respectively, which expire in the years 2017 through 2036. However, during 2016, we concluded that under the Internal Revenue Code change of control limitations, a maximum of $2.9 million and $2.8 million, respectively, would be available for reduction of taxable income and reduced both the deferred tax asset and valuation allowance accordingly. Due to the uncertainty surrounding their realization, we recorded a full valuation allowance against our net deferred tax assets. Accordingly, no deferred tax asset has been recorded in the accompanying condensed consolidated balance sheets.

Marketing Costs

All costs related to marketing and advertising our products are charged to expense as incurred or at the time the advertising takes place. Advertising costs were not material in each of the quarters ended April 1, 2017 and April 2, 2016.

Net Loss Per Share

Basic and diluted net loss per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding in each period. Potential common shares are not included in the calculation of diluted loss per share because their effect is anti-dilutive.

Stock-based Compensation

We grant both restricted stock awards and stock options to our key employees, directors and consultants. For the quarters ended April 1, 2017 and April 2, 2016, no options or awards were granted. The following table presents details of total stock-based compensation expense that is included in each functional line item on our condensed consolidated statements of operations:

 

     Three months ended  
     April 1, 2017      April 2, 2016  

Cost of revenues

   $ —        $ 1,000  

Research and development

     14,000        37,000  

Selling, general and administrative

     89,000        223,000  
  

 

 

    

 

 

 

Total stock-based compensation expense

   $ 103,000      $ 261,000  
  

 

 

    

 

 

 

Use of Estimates

The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. The significant estimates in the preparation of the financial statements relate to the assessment of the carrying amount of accounts receivable, fixed assets, intangibles, estimated provisions for warranty costs, fair value of warrant derivatives, income taxes and disclosures related to litigation. Actual results could differ from those estimates and such differences may be material to the condensed consolidated financial statements.

Fair Value of Financial Instruments

We have estimated the fair value amounts of our financial instruments using the available market information and valuation methodologies considered appropriate. We determined the book value of our cash and cash equivalents, accounts receivable, and other current liabilities as of April 1, 2017 approximate fair value.

The fair value of our warrant derivative liability was estimated using the Binomial Lattice option valuation model.

 

8


Table of Contents

Fair value for financial reporting purposes is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date, ASC 820, “Fair Value Measurement and Disclosures”, also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:

Level 1 — quoted prices in active markets for identical assets or liabilities

Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable

Level 3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

The fair value of our warrant liabilities was determined based on level 3 inputs. These derivative liabilities are adjusted to reflect fair value at each period end, with any increase or decrease in the fair value being recorded in results of operations as adjustments to fair value of derivatives. See Note 3 — Stockholders’ Equity: Warrants.

Comprehensive Income

We have no items of other comprehensive income in any period and consequently have not included a Statement of Comprehensive Income.

Segment Information

We have historically operated in a single business segment: the research, development, manufacture and marketing of high performance products used in cellular base stations. We derived net commercial product revenues primarily from the sales of our AmpLink and SuperPlex products which we sold directly to wireless network operators in the United States. As discussed in this Report, we are adapting our unique HTS material deposition techniques to produce our energy efficient, cost-effective and high performance Conductus wire.

Certain Risks and Uncertainties

Our long-term prospects are dependent upon the successful commercialization and market acceptance or our Conductus wire products. We do not currently have a customer buying significant amounts of our wire products.

Current sales of our wireless products are to wireless network operators in the United States and our product sales have historically been concentrated in a small number of customers. At April 1, 2017, AT&T and Verizon Wireless represented 100% of total net revenues and none of accounts receivable. In 2016, two customers represented 55% and 23% of total net revenues and 41% of accounts receivable. The loss or reduction in sales, or the inability to collect outstanding accounts receivable, from any of these customers could have a material adverse effect on our business, financial condition, results of operations and cash flows.

We currently rely on a limited number of suppliers for key components of our products. The loss of any of these suppliers could have material adverse effects on our business, financial condition, results of operations and cash flows.

In connection with the sales of our commercial products, we indemnify, without limit or term, our customers against all claims, suits, demands, damages, liabilities, expenses, judgments, settlements and penalties arising from actual or alleged infringement or misappropriation of any intellectual property relating to our products or other claims arising from our products. We cannot reasonably develop an estimate of the maximum potential amount of payments that might be made under our indemnity obligations because of the uncertainty as to whether a claim might arise and how much it might total.

3. Stockholders’ Equity

The following is a summary of stockholders’ equity transactions for the three months ended April 1, 2017:

 

     Convertible                    Capital in              
     Preferred Stock      Common Stock      Excess of     Accumulated        
     Shares     Amount      Shares      Amount      Par Value     Deficit     Total  

Balance at December 31, 2016

     333,767     $ —          7,353,714      $ 7,000      $ 316,177,000     $ (302,086,000   $ 14,098,000  

Conversion of Series D preferred stock to common stock

     (4,842     —          3,227,880        3,000        (3,000       —    

Stock-based compensation

          9,334           103,000         103,000  

Net loss

                  (2,629,000     (2,629,000
  

 

 

   

 

 

    

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Balance at April 1, 2017

     328,925     $ —          10,590,928      $ 10,000      $ 316,277,000     $ (304,715,000   $ 11,572,000  
  

 

 

   

 

 

    

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

 

9


Table of Contents

Stock Options

At April 1, 2017, we had two active equity award option plans, the 2003 Equity Incentive Plan and the 2013 Equity Incentive Plan (collectively, the “Stock Option Plan”), although we can only grant new options under the 2013 Equity Incentive Plan. Under our Stock Option Plan, stock awards were made to our directors, key employees, consultants, and non-employee directors and consisted of stock options, restricted stock awards, performance awards, and performance share awards. Stock options were granted at prices no less than the market value on the date of grant. There were no stock option exercises during the three months ended April 1, 2017 or during the three months ended April 2, 2016.

The impact to the condensed consolidated statements of operations for the quarter ended April 1, 2017 on net loss was $98,000 and $0.01 on basic and diluted net loss per common share and for the quarter ended April 2, 2016 the impact was $99,000 and $0.04 on basic and diluted net loss per common share. No stock compensation cost was capitalized during either period. The total compensation cost related to nonvested awards not yet recognized was $321,000 and the weighted-average period over which the cost is expected to be recognized was 10 months at April 1, 2017.

The following is a summary of stock option transactions under our Stock Option Plans at April 1, 2017:

 

     Number of
Shares
    Price Per Share      Weighted
Average
Exercise
Price
     Number of
Options
Exercisable
     Weighted
Average
Exercise
Price
 

Balance at December 31, 2016

     131,158       $3.30 - $921.60      $ 36.03        101,046      $ 45.35  

Granted

     —            —          

Exercised

     —            —          

Canceled

     (28     322.20 -379.80        339.17        
  

 

 

   

 

 

    

 

 

    

 

 

    

 

 

 

Balance at April 1, 2017

     131,130       $3.30 - $921.60      $ 35.96        102,130      $ 45.24  
  

 

 

   

 

 

    

 

 

    

 

 

    

 

 

 

The outstanding options expire on various dates through the end of November 2025. The weighted-average contractual term of options outstanding is 7.4 years and the weighted-average contractual term of stock options currently exercisable is 7.1 years. The exercise prices for these options range from $3.30 to $921.60 per share, for an aggregate exercise price of $4.7 million. At April 1, 2017, no options had an exercise price less than the current market value.

Restricted Stock Awards

The grant date fair value of each share of our restricted stock awards is equal to the fair value of our common stock at the grant date. Shares of restricted stock under awards all have service conditions and vest over one to three years. The following is a summary of our restricted stock award transactions at April 1, 2017:

 

     Number of
Shares
     Weighted
Average Grant
Date Fair Value
 

Balance nonvested at December 31, 2016

     555      $ 41.40  

Granted

     9,334        1.16  

Vested

     (555      41.40  

Forfeited

     —          —    
  

 

 

    

 

 

 

Balance nonvested at April 1, 2017

     9,334      $ 1.16  
  

 

 

    

 

 

 

The impact to the condensed consolidated statements of operations for the three months ended April 1, 2017 was $5,000 and $0.00 on basic and diluted net loss per common share and for the quarter ended April 2, 2016 the impact was $162,000 and $0.06 on basic and diluted net loss per common share. No stock compensation cost was capitalized during the period. The total compensation cost related to nonvested awards not yet recognized was $10,000 and the weighted-average period over which the cost is expected to be recognized was 13 months.

 

10


Table of Contents

Warrants

The following is a summary of outstanding warrants at April 1, 2017:

 

          Common Shares
          Total      Currently
Exercisable
     Price per
Share
    

Expiration Date

(1)

   Warrants related to April 2013 financing      17,127        17,127      $ 81.75      April 26, 2019

(2)

   Warrants related to August 2013 financing      407,825        407,825      $ 1.50      August 9, 2018

(3)

   Warrants related to February 2015 agreement      3,056        3,056      $ 45.05      February 13, 2020

(4)

   Warrants related to March 2015 financing      102,093        102,093      $ 24.49      September 24, 2020

(5)

   Warrants related to March 2015 financing      10,209        10,209      $ 30.61      March 20, 2020

(6)

   Warrants related to October 2015 financing      1,355,171        1,355,171      $ 6.00      October 14, 2020

(7)

   Warrants related to October 2015 financing      90,345        90,345      $ 6.56      October 14, 2020

(8)

   Warrants related to August 2016 financing      535,062        535,062      $ 3.00      February 2, 2022

(9)

   Warrants related to August 2016 financing      49,939        49,939      $ 3.86      August 2, 2021

(10)

   Warrants related to December 2016 financing      6,856,667        6,856,667      $ 2.00      December 14, 2021

Warrants (1) and (3)-(10) are exercisable by paying cash or, solely in the absence of an effective registration statement or prospectus, by cashless exercise for unregistered shares of common stock. The exercise price of the warrants is subject to standard antidilutive provision adjustment in the case of stock dividends or other distributions on shares of common stock or any other equity or equity equivalent securities payable in shares of common stock, stock splits, stock combinations, reclassifications or similar events affecting our common stock, and also, subject to limitations, upon any distribution of assets, including cash, stock or other property to our stockholders. The exercise price of the warrants is not subject to “price-based” anti-dilution adjustment. We have determined that these warrants related to issuance of common stock are subject to equity treatment because the warrant holder has no right to demand cash settlement and there are no unusual anti-dilution rights.

We have determined that warrants (2) are not considered indexed to our common shares under ASC 815-40, and require separate accounting as derivative instruments with changes in fair value recognized in earnings each period. The warrants contain a provision whereby the warrant exercise price would be decreased in the event that future common stock issuances are made at a price less than the then exercise price. Due to the potential variability of their exercise price, these warrants do not qualify for equity treatment, and therefore are recognized as a liability. The warrant liability is adjusted to fair value each reporting period, and any change in value is recognized in the statement of operations. Their initial August 9, 2013 valuation was determined using the binomial lattice valuation model, including an equal probabilities tree and early exercise factor of 30%, the significant weighted average assumptions for estimating the fair value of these warrants were, respectively, as follows: expected life of five years and two years; risk free interest rates of 1.36% and 0.32%; expected volatility of 111% and 116% and; dividend yield of 0% and 0%. The initial fair value at August 9, 2013 was estimated to be approximately $4.2 million.

Using the binomial lattice valuation model, including an equal probabilities tree and early exercise factor of 30%, the fair value of these warrant liabilities at December 31, 2014 and December 31, 2015, respectively, were $5.2 million and $245,000.

Using the binomial lattice valuation model, including an equal probabilities tree and early exercise factor of 30%, the significant weighted average assumptions for estimating the fair value of warrants (2) at December 31, 2016 was as follows: expected life of 1.6 years; risk free interest rates of 1.15% expected volatility of 147% and; dividend yield of 0% and the December 31, 2016 fair value of these warrants was estimated to be $127,000.

Using the binomial lattice valuation model, including an equal probabilities tree and early exercise factor of 30%, the significant weighted average assumptions for estimating the fair value of warrants (6) at April 1, 2017 was as follows: expected life of 1.4 years; risk free interest rates of 1.1% expected volatility of 151% and; dividend yield of 0% and the April 1, 2017 fair value of these warrants was estimated to be $130,000. The fair value of warrants accounted for as derivative liabilities was increased by $3,000 from December 31, 2016 to April 1, 2017.

4. Loss Per Share

Basic and diluted net loss per share is based on the weighted-average number of common shares outstanding.

 

11


Table of Contents

Since their impact would be anti-dilutive, our net loss per common share does not include the effect of the assumed exercise or vesting of the following shares:

 

     April 1, 2017      April 2, 2016  

Outstanding stock options

     131,130        131,557  

Unvested restricted stock awards

     9,334        33,598  

Outstanding warrants

     9,427,494        3,830,128  
  

 

 

    

 

 

 

Total

     9,567,958        3,995,283  
  

 

 

    

 

 

 

Also, the preferred stock convertible into 18,274 shares of common stock was not included since its impact would be anti-dilutive.

5. Commitments and Contingencies

Operating Leases

We lease our offices and production facility under a non-cancelable operating lease in Austin, Texas that expires in April 2020. The lease contains minimum rent escalation clauses that require additional rental amounts after the first year. Rent expense for these leases is recognized on a straight line basis over the minimum lease term. This lease also requires us to pay utilities, insurance, taxes and other operating expenses and contains one five-year renewal option.

For the three months ended April 1, 2017 and April 2, 2016, rent expense was $125,000 and $152,000 respectively.

Patents and Licenses

We have entered into various licensing agreements requiring royalty payments ranging from 0.13% to 2.5% of specified product sales. Certain of these agreements contain provisions for the payment of guaranteed or minimum royalty amounts. In the event that we fail to pay minimum annual royalties, these licenses may automatically become non-exclusive or be terminated. These royalty obligations terminate at various times from 2017 to 2020. Royalty expense totaled $11,000 and $11,000 for the three months ended April 1, 2017 and April 2, 2016, respectively. Under the terms of certain royalty agreements, royalty payments made may be subject to audit. There have been no audits to date and we do not expect future audit adjustments to be significant.

The minimum lease payments under operating leases and license obligations are as follows:

 

Years ending December 31,

   Licenses      Operating Leases  

Remainder of 2017

   $ 45,000      $ 673,000  

2018

     45,000        895,000  

2019

     —          904,000  

2020

     —          221,000  

2021

     —          —    

Thereafter

     —          —    
  

 

 

    

 

 

 

Total payments

   $ 90,000      $ 2,693,000  
  

 

 

    

 

 

 

6. Contractual Guarantees and Indemnities

During our normal course of business, we make certain contractual guarantees and indemnities pursuant to which we may be required to make future payments under specific circumstances. We have not recorded any liability for these contractual guarantees and indemnities in the accompanying condensed consolidated financial statements.

Warranties

We establish reserves for future product warranty costs that are expected to be incurred pursuant to specific warranty provisions with our customers. Our warranty reserves are established at the time of sale and updated throughout the warranty period based upon numerous factors including historical warranty return rates and expenses over various warranty periods.

Intellectual Property Indemnities

We indemnify certain customers and our contract manufacturers against liability arising from third-party claims of intellectual property rights infringement related to our products. These indemnities appear in development and supply agreements with our customers as well as manufacturing service agreements with our contract manufacturers, are not limited in amount or duration and generally survive the expiration of the contract. Given that the amount of potential liabilities related to such indemnities cannot be determined until an infringement claim has been made, we are unable to determine the maximum amount of losses that we could incur related to such indemnities.

 

12


Table of Contents

Director and Officer Indemnities and Contractual Guarantees

We have entered into indemnification agreements with our directors and executive officers which require us to indemnify such individuals to the fullest extent permitted by Delaware law. Our indemnification obligations under such agreements are not limited in amount or duration. Certain costs incurred in connection with such indemnities may be recovered under certain circumstances under various insurance policies. Given that the amount of any potential liabilities related to such indemnities cannot be determined until a lawsuit has been filed against a director or executive officer, we are unable to determine the maximum amount of losses that we could incur relating to such indemnities. Historically, any amounts payable pursuant to such director and officer indemnities have not had a material negative effect on our business, financial condition or results of operations.

We have also entered into severance and change in control agreements with certain of our executives. These agreements provide for the payment of specific compensation benefits to such executives upon the termination of their employment with us.

General Contractual Indemnities/Products Liability

During the normal course of business, we enter into contracts with customers where we agree to indemnify the other party for personal injury or property damage caused by our products. Our indemnification obligations under such agreements are not generally limited in amount or duration. Given that the amount of any potential liabilities related to such indemnities cannot be determined until a lawsuit has been filed, we are unable to determine the maximum amount of losses that we could incur relating to such indemnities. Historically, any amounts payable pursuant to such indemnities have not had a material negative effect our business, financial condition or results of operations. We maintain general and product liability insurance as well as errors and omissions insurance which may provide a source of recovery to us in the event of an indemnification claim.

7. Details of Certain Financial Statement Components and Supplemental Disclosures of Cash Flow Information and Non-Cash Activities

Balance Sheet Data:

 

     April 1, 2017      December 31,
2016
 

Accounts receivable:

     

Accounts receivable-trade

   $ 5,000      $ 13,000  

Less: allowance for doubtful accounts

     (5,000      (5,000
  

 

 

    

 

 

 
   $ —        $ 8,000  
  

 

 

    

 

 

 
     April 1, 2017      December 31,
2016
 

Inventories:

     

Raw materials

   $ 53,000      $ 68,000  
  

 

 

    

 

 

 
   $ 53,000      $ 68,000  
  

 

 

    

 

 

 
     April 1, 2017      December 31,
2016
 

Property and Equipment:

     

Equipment

   $ 11,571,000      $ 11,571,000  

Leasehold improvements

     1,065,000        1,065,000  

Furniture and fixtures

     205,000        205,000  
  

 

 

    

 

 

 
     12,841,000        12,841,000  

Less: accumulated depreciation and amortization

     (9,912,000      (9,350,000
  

 

 

    

 

 

 
   $ 2,929,000      $ 3,491,000  
  

 

 

    

 

 

 

 

13


Table of Contents

Depreciation expense amounted to $562,000 and $561,000 for the three month periods ended April 1, 2017 and April 2, 2016, respectively.

 

     April 1, 2017      December 31,
2016
 

Patents and Licenses:

     

Patents pending

   $ 460,000      $ 566,000  
  

 

 

    

 

 

 

Patents issued

     1,518,000        1,372,000  

Less accumulated amortization

     (954,000      (948,000
  

 

 

    

 

 

 

Net patents issued

     564,000        424,000  
  

 

 

    

 

 

 
   $ 1,024,000      $ 990,000  
  

 

 

    

 

 

 

Amortization expense related to these items totaled $6,000 and $19,000, for the three month periods ended April 1, 2017 and April 2, 2016, respectively. Amortization expenses are expected to total $20,000 for the remainder of 2017 and $30,000 in 2018 and 2019.

 

     April 1, 2017      December 31,
2016
 

Accrued Expenses and Other Long Term Liabilities:

     

Salaries Payable

   $ 52,000      $ 105,000  

Compensated absences

     179,000        144,000  

Compensation related

     20,000        17,000  

Warranty reserve

     8,000        8,000  

Deferred rent

     39,000        37,000  

Other

     159,000        342,000  

Fair value of warrant derivatives

     130,000        127,000  
  

 

 

    

 

 

 
     587,000        780,000  

Less current portion

     (410,000      (608,000
  

 

 

    

 

 

 

Long term portion

   $ 177,000      $ 172,000  
  

 

 

    

 

 

 

 

     For the three months ended,  
     April 1, 2017      April 2, 2016  

Warranty Reserve Activity:

     

Beginning balance

   $ 8,000      $ 23,000  

Additions

     —          —    

Deductions

     —          (13,000
  

 

 

    

 

 

 

Ending balance

   $ 8,000      $ 10,000  
  

 

 

    

 

 

 

8. Subsequent Events

On April 19, 2017, we received $200,000 from the exercise of 133,333 outstanding warrants at $1.50 per share.

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

General

We are a leading company in developing and commercializing high temperature superconductor (“HTS”) materials and related technologies. HTS materials can substantially improve the performance characteristics of electrical systems, reducing power loss, lowering heat generation, and decreasing electrical noise.

Commercialization

Our development efforts over the last 28 years have yielded an extensive patent portfolio as well as critical trade secrets, unpatented technology and proprietary knowledge. STI’s strategic plan is to utilize our core proprietary technology in superconductivity and leverage our proprietary manufacturing processes to build Conductus wire for use in electrical power devices. As discussed above, we are adapting our unique HTS material deposition techniques to produce our energy efficient, cost-effective and high performance Conductus wire technology for next generation power applications. We have identified several large initial target markets for superconducting wire including energy (wind turbines, cables, fault current

 

14


Table of Contents

limiters), medical (NMR (nuclear magnetic resonance) and MRI (magnetic resonance imaging)), science (high performance magnets) and industrial (motors, generators) applications. We are working with leading industry device manufacturers to complete qualification and acceptance testing of Conductus wire. We expect to begin commercial production of Conductus wire in late 2017.

Our development efforts (including those described under “Our Future Business” below) can take a significant number of years to commercialize, and we must overcome significant technical barriers and deal with other significant risks, some of which are set out in our public filings, including in particular the “Risk Factors” included in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2016.

Our Future Business

We have created several unique capabilities and HTS manufacturing systems related to our Conductus wire platform that we are seeking to produce by leveraging our leadership in superconducting technologies, extensive intellectual property and HTS manufacturing expertise.

HTS Wire Platform

Our Conductus wire product development is focused on large markets where the advantages of HTS wire are recognized by the industry. Our initial product roadmap targets three important applications: superconducting high power transmission cable, superconducting fault current limiters (SFCL) and high field magnets.

Superconducting High Power Transmission Cable:

Superconducting high power transmission and distribution cable transmit 5 to 10 times the electrical current of traditional copper or aluminum cables with significantly improved efficiency. HTS power cable systems consist of the cable, which is comprised of 100’s of strands of HTS wire wrapped around a copper core, and the cryogenic cooling system to maintain proper operating conditions. HTS power cables are particularly suited to high load areas such as the dense urban business districts of large cities, where purchases of easements and construction costs for traditional low capacity cables may be cost prohibitive. The primary application for HTS cables is medium voltage feeds to load pockets in dense urban areas. In these high demand zones the grid is often saturated with aging infrastructure. HTS technology brings a considerable amount of power to new locations where the construction of additional transmission to distribution substations, with major transformer assets, is not feasible. Another potential use of HTS power cable is to improve grid power transmission by connecting two existing substations. In dense urban environments many substations often reach capacity limits and require redundant transformer capacity to improve reliability. HTS cables can tie these existing stations together, avoiding very costly transformer upgrades and construction costs.

Superconducting Fault Current Limiter (SFCL):

With power demand on the rise and new power generation sources being added, the grid has become overcrowded and vulnerable to catastrophic faults. Faults are abnormal flows of electrical current like a short circuit. As the grid is stressed, faults and power blackouts increase in frequency and severity. SFCLs act like powerful surge protectors, preventing harmful faults from disabling substation equipment by reducing the fault current to a safer level (20 – 50% reduction) so that the existing switchgear can still protect the grid. Currently, electrical-utilities use massive 80kA circuit breakers, oversized transformers and fuses to prevent faults from damaging their equipment and protecting against surges. However, once a fault has occurred, standard circuit breakers suffer destructive failure and need to be replaced before service can be restored. In addition, Smart Grid and embedded alternative energy generation enhancements will increase the need for SCFLs. Grid operators face a major challenge in moving power safely and efficiently, from generators to consumers, through several stages of voltage transformation step downs and step ups. At each stage, valuable energy is lost in the form of waste heat. Moreover, while demands are continually rising, space for transformers and substations - especially in dense urban areas - is severely limited. Conventional oil-cooled transformers pose a fire and environmental hazard. Compact, efficient superconducting transformers, by contrast, are cooled by safe, abundant and environmentally benign liquid nitrogen. As an additional benefit, these actively-cooled devices will offer the capability of operating in overload, to twice the nameplate rating, without any loss of life to meet occasional utility peak load demands.

Superconducting High Field magnets:

There are a variety of applications that utilize superconducting magnets in order to capitalize on their unique ability to create extremely high magnetic fields. The NMR and MRI machines of today utilize such superconducting magnets for this very reason. Currently, high-field superconducting magnets are manufactured using commercially available superconducting wire such as niobium-titanium (NbTi) or niobium-tin (Nb3Sn). NMR and MRI device manufacturers look towards advances in superconducting technologies to improve the overall performance of their systems by dramatically

 

15


Table of Contents

increasing the magnetic fields while reducing size. High demand for a robust, high performance and low cost superconducting wire has spurred rapid development of a next generation alternative. In the last 10 years, new second generation (2G) Rare Earth, Barium, Copper Oxide (ReBCO) superconducting materials have been proven to drastically increase magnetic field strengths, especially at low temperatures. These advanced ReBCO based superconductors now provide an excellent alternative to NbTi and Nb3Sn based materials.

Results of Operations

Quarter Ended April 1, 2017 compared to the Quarter Ended April 2, 2016

Net revenues decreased by $88,000, or 99%, to $1,000 in the first quarter of 2017 from $89,000 in the first quarter of 2016. The decrease is the result of low sales volume for our wireless communications products. We sell this legacy product to large North American wireless operators whose spending on 3G data networks, where our products are deployed, has become a secondary priority. Sales prices for these wireless products were essentially unchanged. Our largest customer accounted for 100% and 77%, respectively, of our net commercial revenues in the first quarters of 2017 and 2016. This customer generally purchased products through non-binding commitments with minimal lead-times. Consequently, our commercial product revenues can fluctuate dramatically from quarter to quarter based on changes in our customers’ capital spending patterns. Certain customer testing of our new Conductus wire was not completed in the first quarter of 2017 and no sales of our Conductus wire were recorded.

Cost of revenues includes all direct costs, manufacturing overhead, preproduction process development and provision for excess and obsolete inventories. The cost of revenues decreased to $862,000 in the first quarter of 2017 compared to $864,000 for the first quarter of 2016, a decrease of $2,000 or 0.2%. Our cost of revenues includes both variable and fixed cost components. The variable component consists primarily of materials, assembly and test labor, overhead, which includes utilities, transportation costs and warranty costs. The fixed component includes equipment and leasehold depreciation, purchasing expenses and quality assurance costs. As a result, our gross profit margins decrease as revenue and production volumes decline due to lower sales volume and higher amounts of production overhead variances expensed to cost of sales; and our gross profit margins increase as our revenue and production volumes increase due to higher sales volume and lower amounts of production overhead variances expensed to cost of sales.

The following is an analysis of our product gross loss:

 

     For the quarters ended  
     April 1, 2017      April 2, 2016  
     (Dollars in thousands)  

Net product sales

   $ 1      $ 89  

Total cost of product sales

     862        864  
  

 

 

    

 

 

 

Gross loss

   $ (861    $ (775
  

 

 

    

 

 

 

We had a gross loss of $861,000 in the first quarter of 2017 from the sale of our products compared to a gross loss of $775,000 in the first quarter of 2016. We experienced a gross loss in the first quarter of 2016 due to: our preproduction manufacturing efforts to bring our Conductus wire to market and; our sales being insufficient to cover our overhead. As we emphasize improving manufacturing processes and increasing our yields at lower than optimal capacity, we expect gross losses to continue through the third quarter of 2017.

Research and development expenses relate to development of new Conductus wire products and new wire products manufacturing processes. Total expenses totaled $650,000 and $716,000, respectively, in the first quarters of 2017 and 2016. Our 2017 expenses were lower compared to 2016 as a result of our efforts moving from research and development to manufacturing of our new Conductus wire products.

Selling, general and administrative expenses were $1.1 million and $1.2 million, respectively, in the first quarters of 2017 and 2016. Lower, non-cash stock award expenses in 2017 were the principal cause of this decrease.

We had a loss from the adjustment to the fair value of our warrant derivatives of $3,000 in the first quarter of 2017 and a gain of $21,000 in the first quarter of 2016. These fair value adjustments are due to multiple factors including our stock price, as well as our financing activities affecting the warrant exercise price. This warrant liability is adjusted to fair value each reporting period, and any change in value is recognized in the statement of operations. See Note 3 — Stockholders’ Equity: Warrants.

Other income of $5,000 and $3,000 in the first quarters of 2017 and 2016, respectively, was from interest income.

We had a net loss of $2.6 million for both quarters ended April 1, 2017 and April 2, 2016, respectively. The net loss available to common stockholders totaled $0.26 per common share in the first quarter of 2017, compared to a net loss of $1.00 per common share in the first quarter of 2016. The first quarter 2017 decrease in net loss per common share available to common stockholders is largely due to the increase in the number of common shares outstanding.

 

16


Table of Contents

Liquidity and Capital Resources

Cash Flow Analysis

As of April 1, 2017, we had working capital of $7.7 million, including $8.4 million in cash and cash equivalents, compared to working capital of $9.7 million at December 31, 2016, which included $10.5 million in cash and cash equivalents. We currently invest our excess cash in short-term, investment-grade, money-market instruments with maturities of three months or less.

Cash and cash equivalents decreased by $2.1 million from $10.5 million at December 31, 2016 to $8.4 million at April 1, 2017. In the first quarter of 2017, cash was used in operations and we had no investing activities and no financing activities.

Cash used in operations totaled $2.0 million in the first quarter of 2017. We used $1.9 million to fund the cash portion of our net loss and $0.1 million was used by changes in our working capital.

No net cash was used in investing or financing activities in the first quarter of 2017 or 2016.

Financing Activities

We have historically financed our operations through a combination of cash on hand, cash provided from operations, equipment lease financings, available borrowings under bank lines of credit and both private and public equity offerings. There were no financing activities in the first quarter of 2017.

Contractual Obligations and Commercial Commitments

We lease all of our properties. All of our operations, including our manufacturing facilities, are located in Austin, Texas. We occupy 94,000 square feet in Austin, Texas under a non-cancellable long-term lease that expires in April 2020. Although we currently have excess capacity, we believe this facility can be managed in a flexible and cost effective manner and is adequate to meet current and reasonably anticipated needs for the next two years. This lease also includes a renewal option.

We have not had other material changes outside of the ordinary course of business in our contractual obligations as disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016.

Capital Expenditures

We made no investments for fixed assets in the first quarter of 2017. During the remainder of 2017, we expect to make capital expenditures for the purchase of equipment and facilities improvements for our Conductus wire initiative with the actual amount of expenditures related to the levels of our customer orders. We do not plan any additional fixed asset expenditures in 2017 for our existing legacy wireless business.

Future Liquidity

For the quarter ended April 1, 2017, we incurred a net loss of $2.6 million and had negative cash flows from operations of $2.0 million. In the full 2016 year, we incurred a net loss of $11.1 million and had negative cash flows from operations of $8.1 million. Our ability to realize our investment in infrastructure is dependent on market acceptance and realization of significant revenues from Conductus wire products. Our independent registered public accounting firm has included in its audit reports for 2016 and 2015 an explanatory paragraph expressing substantial doubt about our ability to continue as a going concern within one year after the date the condensed consolidated financial statements were issued.

At April 1, 2017, we had $8.4 million in cash and cash equivalents. Our current forecast is that our existing cash resources will be sufficient to fund our planned operations into the first quarter of 2018. Unless we can materially grow our revenues from commercial operations, we will need to raise additional capital during the next 12-months to continue to implement our current business plan and maintain our viability. Additional financing may not be available on acceptable terms or at all. If we issue additional equity securities to raise funds, the ownership percentage of our existing stockholders would be reduced. New investors may demand rights, preferences or privileges senior to those of existing holders of common stock. If we cannot raise any needed funds, we might be forced to make further substantial reductions in our operating expenses, which could adversely affect our ability to implement our current business plan and ultimately our viability as a company. These factors raise substantial doubt about our ability to continue as a going concern.

 

17


Table of Contents

Our plans regarding improving our future liquidity will require us to successfully use our expertise and our technology to generate revenues in various ways, including commercial operations, joint ventures and licenses. We have invested and will continue to invest in our Austin, Texas manufacturing facility to enable us to produce our Conductus wire products. However, delays in the timing of our ability to, including but not limited to, raise additional capital, unexpected production delays, and our ability to sell our Conductus wire products in large scale could substantially impact our estimates used in the determination of expected future cash flows and/or expected future profitability.

Net Operating Loss Carryforward

As of December 31, 2016, we had net operating loss carryforwards for federal and state income tax purposes of $344.3 million and $119.6 million, respectively, which expire in the years 2017 through 2036. However, during 2016, we concluded that under the Internal Revenue Code change of control limitations, a maximum of $2.9 million and $2.8 million, respectively, would be available for reduction of taxable income and reduced both the deferred tax asset and valuation allowance accordingly. Due to the uncertainty surrounding their realization, we recorded a full valuation allowance against our net deferred tax assets. Accordingly, no deferred tax asset has been recorded in the accompanying condensed consolidated balance sheets.

Critical Accounting Policies and Estimates

Our discussion and analysis of our historical financial condition and results of operations are based upon our condensed consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of these condensed consolidated financial statements in conformity with those principles requires us to make estimates of certain items and judgments as to certain future events including for example those related to bad debts, inventories, recovery of long-lived assets (including intangible assets), income taxes, warranty obligations, and contingencies. These determinations, even though inherently subjective and subject to change, affect the reported amounts of our assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. While we believe that our estimates are based on reasonable assumptions and judgments at the time they are made, some of our assumptions, estimates and judgments will inevitably prove to be incorrect. As a result, actual outcomes will likely differ from our accruals, and those differences—positive or negative—could be material. Some of our accruals are subject to adjustment, as we believe appropriate, based on revised estimates and reconciliation to the actual results when available.

On July 18, 2016, we effected a 1-for-15 reverse stock split of our common stock, or the Reverse Stock Split. As a result of the Reverse Stock Split, every fifteen shares of our pre-Reverse Stock Split common stock were combined and reclassified into one share of our common stock. The Reverse Stock Split did not change the authorized number of shares or the par value of our common stock. Share and per share data included herein has been retroactively restated for the effect of the Reverse Stock Split as applicable.

In addition, we identified certain critical accounting policies which affect certain of our more significant estimates and assumptions used in preparing our condensed consolidated financial statements in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016. We have not made any material changes to these policies.

Backlog

Our commercial backlog consists of accepted product purchase orders with scheduled delivery dates during the next twelve months. We had commercial backlog of $43,000 and evaluation and qualification orders with unspecified delivery dates for $45,000 at April 1, 2017 and at December 31, 2016, respectively.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We do not believe that there was a material change in our exposure to market risk at April 1, 2017 compared with our market risk exposure on December 31, 2016. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations Market Risk” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016.

 

Item 4. Controls and Procedures

We have established disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended). As of the end of the period covered by this report we carried out an evaluation under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15 of the Securities and Exchange Act of 1934, as amended. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective.

 

18


Table of Contents

There were no changes in our internal controls over financial reporting during the quarter ended April 1, 2017 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

We do not expect that our disclosure controls and procedures or our internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected.

PART II

OTHER INFORMATION

 

Item 1. Legal Proceedings

From time to time, we are party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of our business. Excluding ordinary, routine litigation incidental to our business, we are not currently a party to any legal proceedings that we believe would reasonably be expected to have a material adverse effect on our business, financial condition or results of operation or cash flow.

 

Item 1A. Risk Factors

A description of the risk factors associated with our business is contained in Item 1A, “Risk Factors,” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2016 filed with the Securities and Exchange Commission on March 30, 2017. We are not aware of any material changes to those risk factors other than as set forth below.

We need to materially grow our revenues from commercial operations or raise additional capital prior to the first quarter of 2018. If we are unable to materially grow our revenues from commercial operations or raise capital our ability to implement our current business plan and ultimately our viability as a company could be adversely affected.

At April 1, 2017, we had $8.4 million in cash and cash equivalents compared to $10.5 million in cash and cash equivalents as of December 31, 2016. Our current forecast is that our existing cash resources will be sufficient to fund our planned operations into the first quarter of 2018. Unless we can materially grow our revenues from commercial operations, we will need to raise additional capital during the next 12-months to continue to implement our current business plan and maintain our viability.

Additional financing may not be available on acceptable terms or at all. If we issue additional equity securities to raise funds, the ownership percentage of our existing stockholders would be reduced. New investors may demand rights, preferences or privileges senior to those of existing holders of common stock and could also require that we issue warrants in connection with sales of our stock. If we cannot raise any needed funds to grow our commercial resources, we might be forced to make changes to, or delay aspects of, our business plan which could adversely affect our ability to implement our current business plan and ultimately our viability as a company.

 

19


Table of Contents

If we fail to maintain the listing of our common stock with a U.S. national securities exchange, the liquidity of our common stock could be adversely affected.

Our common stock is listed for trading on the NASDAQ Capital Market. NASDAQ has adopted a number of continued listing standards that are applicable to our common stock, including a requirement that the bid price of our common stock be at least $1.00 per share. Failure to maintain the minimum bid price can result in the delisting of our common stock from the NASDAQ Capital Market. During 2017 through May 5, 2017, the closing trading price of our common stock on the NASDAQ capital market has generally been between $1.00 per share and $2.00 per share and we have previously fallen out of compliance with the minimum bid price requirement. On July 18, 2016, we effected a one-for-fifteen reverse stock split in connection with regaining compliance with the minimum bid requirement following a notice from the Listing Qualifications Department of the Nasdaq Stock Market on October 30, 2015 and received a notice of re-compliance from the Listing Qualifications Department of the Nasdaq Stock Market on August 2, 2016. We currently have approximately 10,724,261 publicly held shares as of May 6, 2017. Because of NASDAQ’s continued listing standard which requires that we maintain at least 500,000 publicly held shares, our ability to effectuate a reverse split in the future is limited to a reverse split ratio that would maintain compliance with such publicly held share requirement. This effective limit to a reverse split ratio could prevent us from remediating a minimum bid price violation under circumstances where our stock price was substantially below $1.00 and a higher ratio was needed to remediate the noncompliance. If our common stock is delisted by NASDAQ, our common stock may be eligible to trade on the OTC Bulletin Board, OTC QB or another over-the-counter market. Any such alternative would likely result in it being more difficult for us to raise additional capital through the public or private sale of equity securities and for investors to dispose of, or obtain accurate quotations as to the market value of, our common stock. In addition, there can be no assurance that our common stock would be eligible for trading on any such alternative exchange or markets.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

 

Item 3. Defaults Upon Senior Securities

None.

 

Item 4. Mine Safety Disclosures

None.

 

Item 5. Other Information

None.

 

Item 6. Exhibits.

 

Number    Description of Document
  31.1    Statement of CEO Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
  31.2    Statement of CFO Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
  32.1    Statement of CEO Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**
  32.2    Statement of CFO Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**
101.INS    XBRL Instance Document*
101.SCH    XBRL Taxonomy Extension Schema Document*
101.CAL    XBRL Calculation Linkbase Document*
101.DEF    XBRL Taxonomy Extension Definition Linkbase Document*
101.LAB    XBRL Label Linkbase Document*
101.PRE    XBRL Taxonomy Presentation Linkbase Document*

 

* Filed herewith.
** Furnished, not filed.

 

20


Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on our behalf by the undersigned thereunto duly authorized.

 

    SUPERCONDUCTOR TECHNOLOGIES INC.

Dated: May 16, 2017

   

/s/ William J. Buchanan

   

William J. Buchanan

    Chief Financial Officer
   

/s/ Jeffrey A. Quiram

   

Jeffrey A. Quiram

   

President and Chief Executive Officer

 

21